Click for best price
Postpemic Era Retinal Biosimilars Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Global Retinal Biosimilars Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Retinal Biosimilars industry at home and abroad, estimate the overall market scale of the Retinal Biosimilars industry and the market share of major countries, Retinal Biosimilars industry, and study and judge the downstream market demand of Retinal Biosimilars through systematic research, Analyze the competition pattern of Retinal Biosimilars, so as to help solve the pain points of various stakeholders in Retinal Biosimilars industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Retinal Biosimilars Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Retinal Biosimilars Market?
Novartis (Sandoz)
Takeda
Bayer
Genentech
Pfenex
Reliance Life Sciences
Hetero Drugs
Intas Pharmaceuticals
Santo Holding
Regeneron Pharmaceuticals
Major Type of Retinal Biosimilars Covered in XYZResearch report:
Macular Degeneration Drugs
Diabetic Eye Disease Drugs
Macular Pucker Drugs
Others
Application Segments Covered in XYZResearch Market
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Retinal Biosimilars Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
84 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Retinal Biosimilars Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Retinal Biosimilars Market by Value
2.2.1 Global Retinal Biosimilars Revenue by Type
2.2.2 Global Retinal Biosimilars Market by Value
2.3 Global Retinal Biosimilars Market by Sales
2.3.1 Global Retinal Biosimilars Sales by Type
2.3.2 Global Retinal Biosimilars Market by Sales
3. The Major Driver of Retinal Biosimilars Industry
3.1 Historical & Forecast Global Retinal Biosimilars Sales and Revenue (2018-2028)
3.2 Largest Application for Retinal Biosimilars (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Retinal Biosimilars Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Retinal Biosimilars Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Retinal Biosimilars Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Retinal Biosimilars Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Retinal Biosimilars Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Retinal Biosimilars Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Retinal Biosimilars Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Retinal Biosimilars Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Retinal Biosimilars Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Retinal Biosimilars Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Retinal Biosimilars Average Price Trend
13.1 Market Price for Each Type of Retinal Biosimilars in US (2018-2022)
13.2 Market Price for Each Type of Retinal Biosimilars in Europe (2018-2022)
13.3 Market Price for Each Type of Retinal Biosimilars in China (2018-2022)
13.4 Market Price for Each Type of Retinal Biosimilars in Japan (2018-2022)
13.5 Market Price for Each Type of Retinal Biosimilars in India (2018-2022)
13.6 Market Price for Each Type of Retinal Biosimilars in Korea (2018-2022)
13.7 Market Price for Each Type of Retinal Biosimilars in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Retinal Biosimilars in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Retinal Biosimilars Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Retinal Biosimilars
15. Retinal Biosimilars Competitive Landscape
15.1 Novartis (Sandoz)
15.1.1 Novartis (Sandoz) Company Profiles
15.1.2 Novartis (Sandoz) Product Introduction
15.1.3 Novartis (Sandoz) Retinal Biosimilars Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Takeda
15.2.1 Takeda Company Profiles
15.2.2 Takeda Product Introduction
15.2.3 Takeda Retinal Biosimilars Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Bayer
15.3.1 Bayer Company Profiles
15.3.2 Bayer Product Introduction
15.3.3 Bayer Retinal Biosimilars Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Genentech
15.4.1 Genentech Company Profiles
15.4.2 Genentech Product Introduction
15.4.3 Genentech Retinal Biosimilars Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Pfenex
15.5.1 Pfenex Company Profiles
15.5.2 Pfenex Product Introduction
15.5.3 Pfenex Retinal Biosimilars Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Reliance Life Sciences
15.6.1 Reliance Life Sciences Company Profiles
15.6.2 Reliance Life Sciences Product Introduction
15.6.3 Reliance Life Sciences Retinal Biosimilars Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Hetero Drugs
15.7.1 Hetero Drugs Company Profiles
15.7.2 Hetero Drugs Product Introduction
15.7.3 Hetero Drugs Retinal Biosimilars Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Intas Pharmaceuticals
15.8.1 Intas Pharmaceuticals Company Profiles
15.8.2 Intas Pharmaceuticals Product Introduction
15.8.3 Intas Pharmaceuticals Retinal Biosimilars Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Santo Holding
15.9.1 Santo Holding Company Profiles
15.9.2 Santo Holding Product Introduction
15.9.3 Santo Holding Retinal Biosimilars Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 Regeneron Pharmaceuticals
15.10.1 Regeneron Pharmaceuticals Company Profiles
15.10.2 Regeneron Pharmaceuticals Product Introduction
15.10.3 Regeneron Pharmaceuticals Retinal Biosimilars Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Retinal Biosimilars Industry (Volume)
Figure 2. Retinal Biosimilars Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Retinal Biosimilars Revenue in 2022
Figure 5. US Retinal Biosimilars Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Retinal Biosimilars Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Retinal Biosimilars Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Retinal Biosimilars Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Retinal Biosimilars Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Retinal Biosimilars Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Retinal Biosimilars Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Retinal Biosimilars Revenue, by Type (Million USD) (2018-2028)
Table 4. Retinal Biosimilars Sales, by Type (K Unit) (2018-2028)
Table 5. Retinal Biosimilars Sales (K Unit) by Application (2018-2028)
Table 6. Retinal Biosimilars Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Retinal Biosimilars Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Retinal Biosimilars Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Retinal Biosimilars Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Retinal Biosimilars Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Retinal Biosimilars Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Retinal Biosimilars Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Retinal Biosimilars Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Retinal Biosimilars Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Retinal Biosimilars in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Retinal Biosimilars in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Retinal Biosimilars in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Retinal Biosimilars in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Retinal Biosimilars in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Retinal Biosimilars in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Retinal Biosimilars in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Novartis (Sandoz) Profiles
Table 61. Novartis (Sandoz) Retinal Biosimilars Product Introduction
Table 62. Novartis (Sandoz) Retinal Biosimilars Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Novartis (Sandoz) Strategic initiatives
Table 64. Takeda Profiles
Table 65. Takeda Retinal Biosimilars Product Introduction
Table 66. Takeda Retinal Biosimilars Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Takeda Strategic initiatives
Table 68. Bayer Profiles
Table 69. Bayer Retinal Biosimilars Product Introduction
Table 70. Bayer Retinal Biosimilars Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Bayer Strategic initiatives
Table 72. Genentech Profiles
Table 73. Genentech Retinal Biosimilars Product Introduction
Table 74. Genentech Retinal Biosimilars Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Genentech Strategic initiatives
Table 76. Pfenex Profiles
Table 77. Pfenex Retinal Biosimilars Product Introduction
Table 78. Pfenex Retinal Biosimilars Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Pfenex Strategic initiatives
Table 80. Reliance Life Sciences Profiles
Table 81. Reliance Life Sciences Retinal Biosimilars Product Introduction
Table 82. Reliance Life Sciences Retinal Biosimilars Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Reliance Life Sciences Strategic initiatives
Table 84. Hetero Drugs Profiles
Table 85. Hetero Drugs Retinal Biosimilars Product Introduction
Table 86. Hetero Drugs Retinal Biosimilars Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Hetero Drugs Strategic initiatives
Table 88. Intas Pharmaceuticals Profiles
Table 89. Intas Pharmaceuticals Retinal Biosimilars Product Introduction
Table 90. Intas Pharmaceuticals Retinal Biosimilars Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Intas Pharmaceuticals Strategic initiatives
Table 92. Santo Holding Profiles
Table 93. Santo Holding Retinal Biosimilars Product Introduction
Table 94. Santo Holding Retinal Biosimilars Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Santo Holding Strategic initiatives
Table 97. Regeneron Pharmaceuticals Profiles
Table 98. Regeneron Pharmaceuticals Retinal Biosimilars Product Introduction
Table 99. Regeneron Pharmaceuticals Retinal Biosimilars Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Regeneron Pharmaceuticals Strategic initiatives
